Today: 3 June 2026
Denison Mines stock rebounds premarket after 5% slide as uranium names turn choppy again
27 January 2026
1 min read

Denison Mines stock rebounds premarket after 5% slide as uranium names turn choppy again

New York, January 27, 2026, 09:20 EST — Premarket

Denison Mines Corp shares climbed 1.1% to $3.74 in early Tuesday trading, recovering slightly after tumbling 5.1% on heavy volume the day before. The uranium developer saw its stock swing from $3.67 up to $4.05 on Monday.

This shift is significant as uranium-related stocks are now more volatile than the commodity itself, with funds flowing rapidly in and out of the sector. The Global X Uranium ETF dropped 3.6% on Monday but was trading roughly 1.6% higher in pre-market action.

Uranium futures closed Monday at $89.25 a pound, marking a new 52-week peak according to Investing.com’s contract data. Despite rising uranium prices, uranium stocks weakened, leaving traders fixated on positioning and risk appetite ahead of the open.

Denison slid Monday alongside other popular uranium stocks. Cameco dropped 2.2%, Uranium Energy was down 1.5%, and NexGen Energy tumbled 3.2% during the session.

Denison is primarily recognized for its Wheeler River project located in Canada’s Athabasca Basin, along with its planned Phoenix in-situ recovery (ISR) uranium mine. ISR involves injecting fluids underground to dissolve uranium, which is then pumped to the surface, avoiding the need for traditional open-pit or underground mining.

The company announced on Jan. 2 that it’s prepared to give the final investment go-ahead — the official signal to launch major spending — and kick off construction at Phoenix as soon as the last permits come through. CEO David Cates confirmed Denison “stands ready to make a final investment decision and commence construction.” Denison Mines Corp.

Denison’s shares on the TSX (DML) ended Monday at C$5.08 in Toronto, slipping 4.9%, tracking the decline seen in the U.S. market.

Before the open, traders will be watching if Tuesday’s early bounce sticks, and whether the wider uranium market climbs with futures or echoes Monday’s slide in equities.

Still, the stock’s risks hinge on execution and timing: delays in permitting, another surge in construction costs, or a sharp fall in uranium prices could weigh more heavily on developers than producers, since their cash flow remains a future prospect.

Denison is now focused on the regulatory front. It’s waiting on a verdict from Canada’s nuclear regulator following a public hearing. The company has set its sights on securing final construction approvals for Phoenix by Q1 2026.

Latest articles

Archer Aviation trades under $7 as next test looms for air-taxi gamble

Archer Aviation trades under $7 as next test looms for air-taxi gamble

3 June 2026
Archer Aviation shares dipped below $7 premarket after closing at $6.74, as investors weigh heavy cash burn—$217.7 million Q1 net loss, $1.78 billion cash on hand—against hopes for first U.S. eVTOL flights this year; Cantor Fitzgerald cut its price target to $11 but kept an Overweight rating, while 46 disclosed risks and ongoing certification challenges cloud near-term outlook.
Broadcom’s $280 Billion AI Rally Hits Key Test

Broadcom’s $280 Billion AI Rally Hits Key Test

3 June 2026
Broadcom’s stock soared 14% in four days, adding $280 billion in value ahead of Wednesday’s earnings after Alphabet’s $80 billion equity raise spotlighted AI data-center suppliers; with options implying a 9% share move either way, investors await proof that surging AI demand is translating into real revenue growth.
J-Star Stock Moves Up After Texas Battery Update in Pre-Market

J-Star Stock Moves Up After Texas Battery Update in Pre-Market

3 June 2026
J-Star Holding Co. surged to $1.36 in premarket trading after new disclosures on its proposed $122.5 million Baytown, Texas solid-state battery plant, pushing shares above Nasdaq’s $1 minimum less than a week before a key shareholder vote on a reverse split aimed at regaining compliance.
Legend Biotech jumps 42% as traders look at results from small cancer study

Legend Biotech jumps 42% as traders look at results from small cancer study

3 June 2026
Legend Biotech shares soared 42% to $36.28 after early Phase 1 data showed all six higher-dose patients with relapsed or refractory B-cell non-Hodgkin lymphoma responded to its in vivo CAR-T therapy LB2501, with five complete responses; UBS raised its price target to $49, citing the therapy’s outlook, but the results are early and based on a small group with short follow-up.
T1 Energy Stock Falls Premarket After $32M KORE Battery Deal

T1 Energy Stock Falls Premarket After $32M KORE Battery Deal

3 June 2026
T1 Energy shares fell 1.3% premarket after announcing a $32 million KORE Power acquisition to expand into battery storage and AI data-center infrastructure, just a day after a 15.7% stock surge; Northland initiated coverage with an outperform rating and $16 target, but flagged deal execution and funding as key risks.
Ondas stock edges up premarket after 8% slide as Tallinn drone showcase rolls out
Previous Story

Ondas stock edges up premarket after 8% slide as Tallinn drone showcase rolls out

Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps
Next Story

Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps

Go toTop